Medicines and health technology adoption

Life Sciences

Working with you to accelerate appropriate, equitable uptake through clinically embedded digital capabilities. Medicines & health technology adoption

Optum sits at the heart of UK healthcare. Our clinical systems are relied on every day across primary care, pharmacy and community services — forming part of the national infrastructure that supports millions of patient interactions. Because our technology is woven directly into the systems clinicians already use, we’re not observing healthcare from the sidelines. We’re embedded within it — connecting people, pathways and data across the care ecosystem. This position gives us a unique ability to support researchers and life sciences organisations in turning innovation into real-world impact. From advancing clinical research, to enabling appropriate medicines and health technology adoption, to generating high-quality real-world insight, we help bridge the gap between evidence, policy and everyday practice — securely, responsibly and at scale. Together, we’re accelerating progress across medicine and healthcare — moving innovation closer to patients and the clinicians who care for them. Turning innovation into real world care

#1 clinical system supplier in:

Primary care used by 4,600+ GP practices*.

Community pharmacy used by 5,800+ pharmacies*.

A and E acute care used by 30 trusts*.

#2 clinical system supplier in:

Acute hospital pharmacy used by 63 hospital pharmacies*.

Community care used by 37 trusts*.

*Source: Optum

2

3

Life science innovation demands significant investment, robust clinical evidence and regulatory approval — yet even with these in place, progress can stall when it reaches everyday clinical practice. Adoption often slows because: • Clinical guidance is hard to translate into day‑to‑day workflows • Identifying eligible patients at scale is challenging • Uptake varies widely across regions and care settings • Clinicians are under intense pressure, with limited time and visibility These challenges aren’t driven by a lack of clinical intent. They reflect the realities of a stretched, fragmented healthcare system — where even proven innovations can struggle to reach the patients who would benefit most. Where innovation slows

4

5

We operate within the UK healthcare system every day, giving us a practical understanding of how innovation is adopted in real clinical settings. As the leading provider of clinical systems across primary care, community pharmacy and community services, we’re embedded directly Why we are different into the workflows clinicians rely on. This places us where decisions are made, treatments are prescribed and patients are actively managed.

Many of the approaches traditionally used to support clinicians — including education, materials, representatives and external campaigns — sit outside the clinical workflow. While valuable, they don’t always connect with the moments when decisions are being made in practice. Supporting decisions inside the clinical workflow

Those moments tend to occur: • During the GP consultation • At the point of prescribing • During a medication review • At the point of dispensing • When follow‑up or monitoring is due

Aligning support with the clinical workflow helps ensure guidance is available when it is most relevant — fitting naturally into everyday practice and decision‑making.

6

7

We combine market access expertise with the power of our integrated clinical software ecosystem to transform how treatments are identified, prescribed, dispensed, and supported. Our embedded capabilities include: Medicines & health technology adoption

In workflow clinical decision support We bring evidence, guidance and key messages into the clinician’s workflow — at the exact moment a decision is made.

Guideline aligned therapy implementation We digitise key steps in the care pathway to support consistent, guideline‑driven treatment across regions and care settings.

Proactive patient identification & pathway activation Using real‑world clinical data, we surface eligible or at‑risk patients at scale and guide timely, evidence‑aligned actions.

Jump to page

Jump to page

Jump to page

8

9

Together, these digital capabilities help ensure medicines and health technologies move from approval to appropriate use — embedded within everyday care.

Clinical prompts Surface timely, relevant prompts to GPs and Pharmacists within their workflow​ Support clinical decision making and product awareness

Data collection templates Enable structured data capture within community pharmacy settings​ Facilitate consistent reporting and insights generation

Risk‑stratification and pathway activation Identify patient cohorts from medical data. Refer patients to the correct clinical pathway with appropriate data‑sharing permissions

10

11

In workflow clinical decision support Where it works: GP and pharmacy systems We help your treatment reach the clinician at the moment it matters by surfacing:

Clinical prompt for healthcare professionals (HCPs) Our free consultancy service will help you to curate the right type of alert for the HCP audience based on suitability and clinical impact needed

Find patients based on existing codes on their record

• Eligibility prompts • Therapy guidance • Safety & monitoring triggers • Referral reminders • Pharmacy dispensing prompts

Prompt to the HCP will automatically load at the point the HCP selects the patients record to initiate a consultation Provide a prompt to the HCP to take an action such as a medication review

This ensures the right information appears at the exact point of need — improving confidence, safety and uptake.

12

13

Therapeutic signposting for pharmacists

Therapeutic signposting for patients After completing the dispensing process, the following onscreen alert is presented before the drug label is printed

Pharmacist / Dispenser selects appropriate drug/s once presented with a prescription; the following flash alert is presented on screen

Pharmacist / Dispenser has the option to print the on-screen alert for their information

Pharmacist / dispenser has the option to print on-screen alert for the patient

MHRA guidance divides Anti Epileptic Drugs into three categories according to the importance of maintaining a consistent supply and depending on whether there is consistent to be a risk of problems if switching between different versions.

For continuity of care and control of your condition Please ensure this is your regular brand of Carbamazepine, if this differs, please inform your pharmacist.

Please scan here for more information

10/06/2020

Ms A Test

Pharmacy Pharmacy Address WD2 5WH

cont....

Ms A Test Pharmacy Pharmacy Address WD2 5WH

.........................

10/06/2020

Carbamazepine falls into category 1. Specific measures are necessary to ensure brand continuity. For more information on this guidance please see https://bnf.nice.org.uk/treatment-summary/epilep sy.html

A QR code can display a link to the sponsor’s website for the patient to read in their own time

10/06/2020

Ms A Test

Pharmacy Pharmacy Address WD2 5WH

14

15

Guideline aligned therapy implementation Where it works: GP, pharmacy and community care We help turn guidance into repeatable, digital steps clinicians can follow:

Patient assessment and monitoring in the pharmacy

Service visible to accredited providers:

Customisable consultation questions:

1

3

18 Month Follow-Up

1. Patient assessment 2. Therapy initiation 3. Dose titration 4. Monitoring 5. Referral 6. Follow-up

Find patient via the Personal Demographic Service (PDS):

2

Real-time auditing:

4

This reduces unwarranted variation, supports equity, and ensures your therapy is adopted consistently across regions.

16

17

Proactive patient identification & pathway activation Where it works: GP systems and ICS analytics We find patients who meet your criteria using real world clinical data: 1. Diagnoses 2. Comorbidities 3. Lab data 4. Prescribing history 5. Risk scores 6. Guideline aligned eligibility Once identified, automated workflows help bring patients into review, treatment, referral or monitoring — moving them through the pathway quickly and safely.

Building clinical pathways

Build your module Develop a bespoke configuration of actions for HCPs to undertake against your desired cohort Identify patients Deploy the module to identify patients from their healthcare record data for GP action Manage care GPs activate the module, review the list and undertake the required actions on patients including sharing patients to other care providers as needed

18

19

Real-world impact you can achieve with us Our embedded digital capabilities have already improved real world uptake and outcomes: • Heart failure: 10,000+ titration entries → improved optimisation • CKD: 52,000 screened → 2,023 high-risk patients surfaced • Hepatitis C: 583 identified → 79 tested • AF: treatment timelines reduced from 30 months → 10 weeks • Pharmacy interventions: Hundreds of thousands of clinical prompts viewed per each campaign • COVID-19: 23.5 million booster vaccines recorded in 2022

Our strengths Our suite of features enables the end-to-end provision of critical clinical decision support amongst HCPs, whilst providing a channel to both educate patients on therapeutic areas whilst enabling direct feedback and input via electronic data capture.

Integrated ecosystem

Clinically-led solutions

Analytics expertise

End-to-end market access

Scalable and interoperable

20

21

Let’s bring innovation closer to patients

Plan smarter

Match patients with precision

Deliver consistent care

Enhance clinical decisions

Turn evidence into performance

Ready to bring innovation into everyday care? talk to our team .

uk.info@optum.com

22

23

Egton Medical Information Systems Ltd (t/a Optum) is a company registered in England and Wales. Registered number: 02117205. Registered office: Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA. © 2026 Optum. All rights reserved.